Table 2.

Recommended drugs[43]

One of the candidate drugs in the treatment of SARS-CoV-2, which prevents viral replication through direct intervention and increases the body immune response	Interferon-alpha (IFN α)
it was first known as a protease inhibitor in the synthesis and replication of human immunodeficiency virus (HIV), which causes the virus to produce immature and non-infectious particles. Evidence has proven that lopinavir/ritonavir alone or with other viral drugs has been shown to be effective in the treatment of SARS or MERS	Lopinavir/ritonavir (Kaletra)
it is a nucleoside analogue with extensive antiviral activity that can prevent RNA and DNA replication in the virus. It has been used to treat patients with SARS alone or in combination with steroids. It can be considered as a candidate in the treatment of SARS-CoV-2	Ribavirin
It is a low-cost, low-risk anti-malarial drug that has been also used as a drug against autoimmune diseases for more than 70 years. It effectively suppresses SARS-CoV-2, in vitro[43]	Chloroquine
it is an antiviral drug against influenza infection, and has an acceptable in vitro inhibitory effect on reducing SARS-CoV replication. A retrospective cohort study found that Arbidol alone or in combination with other antiviral drugs had favorable outcomes in the treatment of COVID-19 pneumonia.	Arbidol (umifenovir)
there are reports of SARS-CoV and MERS-CoV inhibition in the body. An in vitro study showed that the drug blocked SARSCoV-2 at low micromolecular concentrations	Remdesivir